NIMI
SAGE

Natixis Investment Managers International’s Sage Therapeutics SAGE Stock Holding History

Natixis Investment Managers International’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,200
Closed -$501K – 717
2018
Q2 		$501K Hold
3,200
– – 0.03% 411
2018
Q1 		$515K Buy
+3,200
New +$543K 0.04% 260

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Natixis Investment Managers International's SAGE Position: Q3 2018 in Review

Natixis Investment Managers International sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 3,200 shares — an estimated $501K sold.

Natixis Investment Managers International first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $515K in Q1 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Natixis Investment Managers International reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Natixis Investment Managers International sold 3,200 Sage Therapeutics shares in Q3 2018, an estimated $501K.
  • Natixis Investment Managers International first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • Natixis Investment Managers International's Sage Therapeutics position peaked at $515K in Q1 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Natixis Investment Managers International's 13F filing for Q3 2018, filed 14 Nov 2018.